-
1 Comment
Integral Diagnostics Limited is currently in a long term uptrend where the price is trading 13.3% above its 200 day moving average.
From a valuation standpoint, the stock is 98.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.0.
Integral Diagnostics Limited's total revenue rose by 29.6% to $172M since the same quarter in the previous year.
Its net income has increased by 82.9% to $20M since the same quarter in the previous year.
Finally, its free cash flow grew by 354.2% to $17M since the same quarter in the previous year.
Based on the above factors, Integral Diagnostics Limited gets an overall score of 5/5.
| Industry | Diagnostics & Research |
|---|---|
| Exchange | AU |
| CurrencyCode | AUD |
| ISIN | AU000000IDX2 |
| Sector | Healthcare |
| Dividend Yield | 2.4% |
|---|---|
| PE Ratio | 118.0 |
| Target Price | 3.1516 |
| Market Cap | 879M |
| Beta | 0.26 |
Integral Diagnostics Limited, a healthcare services company, engages in the provision of diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides positron emission tomography, magnetic resonance imaging, and other radiology services. The company was founded in 1967 and is headquartered in Melbourne, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IDX.AU using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
